Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity

被引：8
|
作者：
Zarifa, Abdulrazzak [1 ]
Lopez-Mattei, Juan [2 ]
Palaskas, Nicolas [2 ]
Iliescu, Cezar [2 ]
Durand, Jean-Bernard [2 ]
Kim, Peter Y. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Div Internal Med, Houston, TX 77030 USA
来源：
IMMUNOTHERAPY, 3RD EDITION | 2020年 / 1244卷
关键词：
Immune checkpoint inhibitors; Anti-CTLA4; Anti-PD1; Anti-PDL1; Cardiotoxicity; Myocarditis; COMBINATION; CANCER; TREMELIMUMAB; MYOCARDITIS; SAFETY; IMMUNOTHERAPY; INFLAMMATION; TAMPONADE; NIVOLUMAB; BLOCKADE;
D O I：
10.1007/978-3-030-41008-7_15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The growing success of immune checkpoint inhibitors (ICIs) has led to effectively treating several types of cancers. Even though their use has been associated with the development of cardiac adverse effects, which may decrease the overall survival in cancer patients. These cardiac toxicities are thought to be the result of targeting specific checkpoint proteins on normal myocardial cells leading to over stimulation of the immune system as well as secondary downstream off-target effects on normal tissue. Although cardiotoxicities related to immunotherapy are reportedly rare, they can be severe and associated with life-threatening conditions such as fulminant myocarditis, hemodynamic instability, and cardiac arrest. We will review the most commonly reported cardiovascular toxicities associated with ICIs and their management.
引用
收藏
页码：277 / 285
页数：9
相关论文
共 50 条
  • [41] Advances in immune checkpoint inhibitors induced-cardiotoxicity
    Li, Xiang
    Peng, Wenying
    Wu, Jiao
    Yeung, Sai-Ching Jim
    Yang, Runxiang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology
    Tabata, Mika M.
    Choi, Sara
    Hirotsu, Kelsey
    Kwong, Bernice
    Soleymani, Teo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 986 - 994
  • [43] Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)
    Prawira, A.
    Stundzia, A. B.
    Dufort, P.
    Halankar, J.
    Paravasthu, D. M.
    Spreafico, A.
    Hansen, A. R.
    Razak, A. R. Abdul
    Bedard, P. L.
    Butler, M.
    Lheureux, S.
    Oza, A. M.
    Jang, R. W.
    Suta, K. M.
    Boross-Harmer, S.
    Cipollone, J.
    Chow, H.
    Metser, U.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)
    Durbin, Sienna
    Zubiri, Leyre
    Perlman, Katherine
    Molina, Gabriel
    Jacoby, Ted
    Shah, Nishi
    Reynolds, Kerry Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
    Tie, Emilia Nan
    Lai-Kwon, Julia Elizabeth
    Na, Lumine
    Rtshiladze, Michael Alexander
    Bozzi, James
    Read, Tavis
    Atkinson, Victoria
    Au-Yeung, George
    Long, Georgina V.
    McArthur, Grant A.
    Sandhu, Shahneen Kaur
    Saw, Robyn
    Walpole, Euan Thomas
    Menzies, Alexander M.
    Smithers, B. Mark
    Gyorki, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
    Das, Satya
    Ciombor, Kristen Keon
    Haraldsdottir, Sigurdis
    Pumpalova, Yoanna S.
    Sahin, Ibrahim Halil
    Shyr, Yu
    Chu, Shih-Kai
    Lin, Emily Pei-Ying
    Hsu, Chih-Yuan
    Goff, Laura Williams
    Cardin, Dana Backlund
    Bilen, Mehmet Asim
    Berlin, Jordan
    Wu, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience
    Virik, K.
    Basulaiman, B.
    Robinson, A.
    Hopman, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S868 - S868
  • [48] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [49] Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
    Kizawa, Rika
    Miura, Yuji
    Oda, Yasuhiro
    Nagaoka, Yukiko
    Ozaki, Yukinori
    Kondoh, Chihiro
    Moriguchi, Shuhei
    Takahashi, Yui
    Ogawa, Kazumasa
    Tanabe-Hashimoto, Yuko
    Taniguchi, Shuichi
    Okaneya, Toshikazu
    Kishi, Akiko
    Hayashi, Nobukazu
    Kishi, Kazuma
    Takano, Toshimi
    Masuda, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
    Kizawa, R.
    Miura, Y.
    Oda, Y.
    Nagaoka, Y.
    Masuda, J.
    Ozaki, Y.
    Kondoh, C.
    Moriguchi, S.
    Takahashi, Y.
    Ogawa, K.
    Hashimoto, Y. Tanabe
    Taniguchi, S.
    Okaneya, T.
    Kishi, A.
    Hayashi, N.
    Takaya, H.
    Takano, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345